This inventor holds 1 USPTO granted patent. Top assignee: Ophidian Pharmaceuticals, Inc.. Active years: 2000.
Company Filing History:
Years Active: 2000
Title: Jaeseob Kim: Innovator in TGF-β Pathway Research
Introduction
Jaeseob Kim is a prominent inventor based in Madison, WI (US). He has made significant contributions to the field of biotechnology, particularly in the study of the TGF-β pathway. His innovative work has led to the development of valuable compositions and methods that enhance our understanding of this critical biological pathway.
Latest Patents
Jaeseob Kim holds 1 patent for his invention titled "Compositions and methods for identifying and testing TGF-β pathway." This invention provides compositions and methods for identifying and testing TGF-β pathway agonists and antagonists. It specifically includes compositions comprising Mothers against DPP (MAD) proteins and related Smad polypeptides that exhibit sequence-specific DNA-binding activity. Additionally, the invention introduces novel DNA sequences (SEQ ID NO:19; SEQ ID NO:20; SEQ ID NO:21) that are bound with high affinity by Drosophila MAD protein. This protein is instrumental in identifying compounds that can enhance or interfere with MAD protein-DNA binding.
Career Highlights
Jaeseob Kim is currently associated with Ophidian Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work is pivotal in the exploration of therapeutic applications related to the TGF-β pathway.
Collaborations
Jaeseob Kim collaborates with notable colleagues, including Allen Laughon and Kirby Johnson, who contribute to his research endeavors and help drive innovation in the field.
Conclusion
Jaeseob Kim's contributions to the understanding of the TGF-β pathway through his innovative patent highlight his role as a key inventor in biotechnology. His work not only advances scientific knowledge but also has the potential to lead to significant therapeutic developments.